查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602399

急性復發性癲癇市場：依產品、最終用途分類 - 2025-2030 年全球預測

Acute Repetitive Seizures Market by Product (AZ-002, Diastat Rectal Gel, NRL-1), End-use (Clinics, Hospital) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，急性復發性癲癇市場價值為94.7億美元，預計到2024年將達到104.6億美元，複合年成長率為10.82%，預計到2030年將達到194.6億美元。

急性復發性癲癇發作 (ARS) 是癲癇患者常見的一種病症，其特徵是癲癇發作快速連續發生，且兩次癲癇發作之間沒有完全恢復。需要解決 ARS 的原因是它有可能升級為癲癇持續狀態（一種危及生命的疾病），及時干預至關重要。急性發作管理的應用包括使用速效藥物和介入通訊協定來穩定患者的病情。有效的 ARS 介入措施主要由醫院、急診室和門診的醫療保健專業人員使用，是癲癇管理策略的重要組成部分。市場成長受到人們對癲癇認知的提高、診斷方法的進步以及神經系統疾病盛行率上升等因素的顯著影響。特別是，導致新型治療方法和個人化醫療的研究激增，為技術創新開闢了新的途徑，包括研究和開發適合不同患者需求的快速、易於使用的治療方案。然而，市場開拓面臨挑戰，包括醫藥品認證過程中的監管障礙、新興市場的認知度低以及現有治療方法的潛在副作用和限制。為了克服這些挑戰，我們需要積極投資教育並加強調查方法。遠端醫療整合、數位健康解決方案和攜帶式癲癇管理設備存在著有希望的機會，這些設備可以透過遠端監控和及時干預來改善患者的治療結果。此外，製藥公司和科技公司之間的合作可以刺激創新療法和技術支援的醫療保健解決方案的開發。繼續關注基於遺傳和生物標記研究的個人化醫療方法將有助於制定更有效、更有針對性的治療方法。市場的本質是動態的，並受到技術進步和監管環境的高度影響，需要相關人員的敏捷性和積極適應，以有效地利用成長潛力。

主要市場統計
基準年[2023] 94.7億美元
預測年份 [2024] 104.6億美元
預測年份 [2030] 194.6億美元
複合年成長率（%） 10.82%

市場動態：針對快速發展的急性複發性癲癇市場揭示的關鍵市場見解

供需的動態交互作用正在改變急性復發性癲癇市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 癲癇盛行率不斷增加以及有效治療方法的需求
    • 提高癲癇管理意識
    • 急性復發性發作的臨床試驗數量增加
  • 市場限制因素
    • 診斷、管理和治療癲癇疾病的高成本
  • 市場機會
    • 介紹有效的治療方法和新藥物
    • 提高急性復發性癲癇治療的核准率
  • 市場挑戰
    • 治療急性反覆發作的藥物的副作用

波特的五力：駕馭急性復發性癲癇市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解急性復發性癲癇市場的外部影響

外部宏觀環境因素在塑造急性復發性癲癇市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解急性復發性癲癇市場的競爭格局

對急性復發性癲癇市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣急性複發性癲癇市場供應商的績效評估

FPNV 定位矩陣是評估急性復發性癲癇市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了急性複發性癲癇市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對急性復發性癲癇市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癲癇盛行率不斷上升，需要有效的治療
      • 提高對急性復發性發作管理的認知
      • 急性復發性發作的臨床試驗數量增加
    • 抑制因素
      • 診斷、管理和治療癲癇疾病的費用高昂
    • 機會
      • 介紹有效的治療方法和新藥物
      • 急性復發性癲癇治療藥物核准率提高
    • 任務
      • 治療急性反覆發作的藥物的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 急性復發性癲癇市場：依產品

  • AZ-002
  • Diastat直腸凝膠
  • NRL-1
  • USL-261

第7章 急性復發性癲癇市場：依最終用途分類

  • 診所
  • 醫院

第8章美洲急性復發性癲癇市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區急性復發性癲癇市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲/中東/非洲急性複發性癲癇市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Acorda Therapeutics, Inc.
  • Aculys Pharma, Inc.
  • Aquestive Therapeutics, Inc.
  • Bausch Health Companies Inc.
  • Epalex Corp.
  • Jazz Pharmaceuticals, Inc.
  • Lupin Limited
  • MonoSol Rx LLC
  • Neurelis, Inc.
  • Pharmanovia
  • Proximagen Limited
  • SK Biopharmaceuticals Co., Ltd.
  • UCB SA
  • Upsher-Smith Laboratories, Inc.
  • Veriton Pharma Ltd.
  • Xeris Biopharma Holdings, Inc.
Product Code: MRR-C002B1C99762

The Acute Repetitive Seizures Market was valued at USD 9.47 billion in 2023, expected to reach USD 10.46 billion in 2024, and is projected to grow at a CAGR of 10.82%, to USD 19.46 billion by 2030.

Acute Repetitive Seizures (ARS) refer to a condition characterized by a series of seizures occurring in short succession without a complete recovery between them, often seen in patients with epilepsy. The necessity for addressing ARS lies in its potential to escalate into status epilepticus, a life-threatening condition, making timely intervention crucial. The application of acute seizure management involves the use of fast-acting medications and intervention protocols to stabilize patients. Predominantly utilized by healthcare professionals in hospitals, emergency settings, and outpatient care, effective ARS interventions form a critical component of epilepsy management strategies. Market growth is significantly influenced by factors such as increased awareness of epilepsy, advancements in diagnostic modalities, and the rising prevalence of neurological disorders. Notably, the surge in research leading to novel therapeutic approaches and personalized medicines opens new avenues for innovation, particularly in the development of rapid-onset, user-friendly treatment options suitable for diverse patient needs. However, market expansion faces challenges, including regulatory hurdles in drug approval processes, limited awareness in developing regions, and potential side effects or limitations of existing treatments. These challenges necessitate a robust investment in educational initiatives and enhanced research methodologies to overcome barriers. Promising opportunities exist in telemedicine integration, digital health solutions, and portable seizure management devices, which can enhance patient outcomes by enabling remote monitoring and timely intervention. Additionally, collaboration between pharmaceutical companies and technology firms can spur the development of innovative therapeutic agents and tech-enabled healthcare solutions. Continued focus on personalized medicine approaches based on genetic and biomarker studies can aid in tailoring more effective and targeted therapies. The market's nature is dynamic, heavily influenced by technological advancements and regulatory landscapes, necessitating agility and proactive adaptation from stakeholders to leverage growth potentials effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 9.47 billion
Estimated Year [2024] USD 10.46 billion
Forecast Year [2030] USD 19.46 billion
CAGR (%) 10.82%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Repetitive Seizures Market

The Acute Repetitive Seizures Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of epilepsy and need for efficient treatmnets
    • Increasing awareness regarding management of acute repetitive seizures
    • Rise in number of clinical trials in acute repetitive seizures
  • Market Restraints
    • High cost associated with diagnosing, managing, and treating seizure disorders
  • Market Opportunities
    • Introduction of effective treatment and novel drugs
    • Rise in approval rate for drugs for acute-repetitive-seizures
  • Market Challenges
    • Side effects of medications prescribed during acute-repetitive-seizures

Porter's Five Forces: A Strategic Tool for Navigating the Acute Repetitive Seizures Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Repetitive Seizures Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Repetitive Seizures Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Repetitive Seizures Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Repetitive Seizures Market

A detailed market share analysis in the Acute Repetitive Seizures Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Repetitive Seizures Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Repetitive Seizures Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Repetitive Seizures Market

A strategic analysis of the Acute Repetitive Seizures Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Repetitive Seizures Market, highlighting leading vendors and their innovative profiles. These include Acorda Therapeutics, Inc., Aculys Pharma, Inc., Aquestive Therapeutics, Inc., Bausch Health Companies Inc., Epalex Corp., Jazz Pharmaceuticals, Inc., Lupin Limited, MonoSol Rx LLC, Neurelis, Inc., Pharmanovia, Proximagen Limited, SK Biopharmaceuticals Co., Ltd., UCB S.A., Upsher-Smith Laboratories, Inc., Veriton Pharma Ltd., and Xeris Biopharma Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Acute Repetitive Seizures Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across AZ-002, Diastat Rectal Gel, NRL-1, and USL-261.
  • Based on End-use, market is studied across Clinics and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of epilepsy and need for efficient treatmnets
      • 5.1.1.2. Increasing awareness regarding management of acute repetitive seizures
      • 5.1.1.3. Rise in number of clinical trials in acute repetitive seizures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with diagnosing, managing, and treating seizure disorders
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of effective treatment and novel drugs
      • 5.1.3.2. Rise in approval rate for drugs for acute-repetitive-seizures
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects of medications prescribed during acute-repetitive-seizures
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acute Repetitive Seizures Market, by Product

  • 6.1. Introduction
  • 6.2. AZ-002
  • 6.3. Diastat Rectal Gel
  • 6.4. NRL-1
  • 6.5. USL-261

7. Acute Repetitive Seizures Market, by End-use

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Hospital

8. Americas Acute Repetitive Seizures Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Acute Repetitive Seizures Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Acute Repetitive Seizures Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Acorda Therapeutics, Inc.
  • 2. Aculys Pharma, Inc.
  • 3. Aquestive Therapeutics, Inc.
  • 4. Bausch Health Companies Inc.
  • 5. Epalex Corp.
  • 6. Jazz Pharmaceuticals, Inc.
  • 7. Lupin Limited
  • 8. MonoSol Rx LLC
  • 9. Neurelis, Inc.
  • 10. Pharmanovia
  • 11. Proximagen Limited
  • 12. SK Biopharmaceuticals Co., Ltd.
  • 13. UCB S.A.
  • 14. Upsher-Smith Laboratories, Inc.
  • 15. Veriton Pharma Ltd.
  • 16. Xeris Biopharma Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. ACUTE REPETITIVE SEIZURES MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE REPETITIVE SEIZURES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ACUTE REPETITIVE SEIZURES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ACUTE REPETITIVE SEIZURES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ACUTE REPETITIVE SEIZURES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ACUTE REPETITIVE SEIZURES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ACUTE REPETITIVE SEIZURES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ACUTE REPETITIVE SEIZURES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ACUTE REPETITIVE SEIZURES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ACUTE REPETITIVE SEIZURES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACUTE REPETITIVE SEIZURES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACUTE REPETITIVE SEIZURES MARKET DYNAMICS
  • TABLE 7. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY AZ-002, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY DIASTAT RECTAL GEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY NRL-1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY USL-261, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ACUTE REPETITIVE SEIZURES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ACUTE REPETITIVE SEIZURES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ACUTE REPETITIVE SEIZURES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM ACUTE REPETITIVE SEIZURES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ACUTE REPETITIVE SEIZURES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. ACUTE REPETITIVE SEIZURES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. ACUTE REPETITIVE SEIZURES MARKET, FPNV POSITIONING MATRIX, 2023